Decentralized Autonomous Organizations in the Pharmaceutical Sector: A Paradigm Shift in Research, Development, and Governance

Abstract

The pharmaceutical industry plays an important role in protecting community health by researching, developing and distributing drugs to prevent and cure illnesses. As an integral part of healthcare industry, it faces several challenges such as rising research and development costs, extended approval timelines, supply chain inefficiencies and low patient involvement. This paper examines role of decentralized autonomous organizations (DAOs) in addressing these challenges. It reviews DAO frameworks, decision-making models, reward mechanism, and roles of stakeholders using case studies such as VitaDAO and Molecule to explain their functioning and adoption of DAOs in pharmaceutical industry. DAOs offer a promising alternative to traditional hierarchical systems by promoting innovation and empowering stakeholders. To advance drug discovery and development, DAOs provide a shared platform for scientists, patients, funding agencies and regulatory authorities to work in a democratic and collaborative way to make decisions and manage operations in drug industry. Despite its several benefits, DAOs also face significant challenges, including regulatory uncertainty, data protection, and ensuring longterm sustainability. Future directions include integration of AI into pharmaceutical DAOs, privacy-enhanced DAOs, and cross-DAO cooperation to promote global collaboration across borders.